CAMP4 Therapeutics (NASDAQ:CAMP) Lowered to Strong Sell Rating by Zacks Research

CAMP4 Therapeutics (NASDAQ:CAMP) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Wednesday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. Rodman & Renshaw initiated coverage on shares of CAMP4 Therapeutics in a research note on Tuesday, April 14th. They set a “buy” rating and a $7.00 price target on the stock. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Leerink Partners raised their price objective on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a research note on Thursday, April 2nd. Finally, Chardan Capital set a $6.50 price objective on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, CAMP4 Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $8.36.

CAMP4 Therapeutics Price Performance

CAMP opened at $3.90 on Wednesday. The business has a 50 day simple moving average of $4.28 and a 200-day simple moving average of $4.56. The stock has a market capitalization of $202.53 million, a P/E ratio of -1.65 and a beta of 0.10. CAMP4 Therapeutics has a 12 month low of $1.32 and a 12 month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. The business had revenue of $1.29 million during the quarter. Research analysts anticipate that CAMP4 Therapeutics will post -0.84 EPS for the current year.

Institutional Investors Weigh In On CAMP4 Therapeutics

Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE acquired a new position in CAMP4 Therapeutics during the fourth quarter worth about $86,000. Bridgeway Capital Management LLC acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at approximately $36,000. Two Sigma Investments LP purchased a new position in shares of CAMP4 Therapeutics during the 3rd quarter worth approximately $292,000. Vivo Capital LLC purchased a new position in shares of CAMP4 Therapeutics during the 3rd quarter worth approximately $11,765,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of CAMP4 Therapeutics during the 4th quarter worth approximately $61,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.